Results 21 to 30 of about 1,377,517 (218)

Evaluation of the Antiviral Potential of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of Chikungunya Virus (CHIKV). [PDF]

ACS Omega, 2019
Abstract Antiviral therapy is crucial for the circumvention of viral epidemics. The unavailability of a specific antiviral drug against the chikungunya virus (CHIKV) disease has created an alarming situation to identify or develop potent chemical molecules for remedial management of CHIKV.
Puranik NV, Rani R, Singh VA, Tomar S, Puntambekar HM, Srivastava P.   +5 more
europepmc   +5 more sources

Mathematical analysis and control of chikungunya (CHIKV) virus by SEIR model

International journal of health sciences, 2022
Chikungunya is a re-emerging arboviral disease in Asia and Africa infected by Aedes mosquitoes which had posed a global threat in several countries. Vector borne diseases are the primary cause of death in most of the world countries, hence it becomes pertinent to control these vector borne diseases.
Seema Singla, Madhuchanda Rakshit
openaire   +1 more source

Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine [PDF]

The Journal of Infectious Diseases, 2019
Abstract Background Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after 1 week, but chronic arthralgia can persist for years.
Lisa Henss, Constanze Yue, Christine von Rhein, Roland Tschismarov, Lia-Laura Lewis-Ximenez, Albert Dölle, Sally A. Baylis, Barbara S. Schnierle   +7 more
openaire   +3 more sources

Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy

, 2022
Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based on clinical manifestations.
Fleury Augustin Nsole Biteghe, Chalomie Nyangone Ekome Toung, Jean De La Croix Ndong, Neelakshi Mungra, Tahir B. Dar, Arnaud John Kombe Kombe   +5 more
openaire   +2 more sources

Comodulation of Dengue and Chikungunya Virus Infection During a Coinfection Scenario in Human Cell Lines

Frontiers in Cellular and Infection Microbiology, 2022
The Dengue virus (DENV) and Chikungunya virus (CHIKV) are the arboviruses that pose a threat to global public health. Coinfection and antibody-dependent enhancement are major areas of concern during DENV and CHIKV infections, which can alter the clinical
Debjani Taraphdar, Bharati Singh, Bharati Singh, Sabyasachi Pattanayak, Avula Kiran, Avula Kiran, Poornima Kokavalla, Mohd. Faraz Alam, Mohd. Faraz Alam, Gulam Hussain Syed   +9 more
doaj   +1 more source

Optimum level of NEDD4 and its interaction with nsP3 are crucial to facilitate efficient Chikungunya virus (CHIKV) infection. [PDF]

J Gen Virol
Chikungunya is a febrile infection caused by the Chikungunya virus (CHIKV), an alphavirus which has emerged as a serious public health problem globally. Despite extensive research, our understanding of different host factors facilitating effective CHIKV infection is not clear yet. NEDD4, a member of the E3 ubiquitin ligase, is one such protein.
Verma S, Chatterjee S, Keshry SS, Dhal AK, Bhowmick B, Newar J, Chattopadhyay S, Ghatak A.   +7 more
europepmc   +3 more sources

Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate [PDF]

Vaccines, 2018
Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS.
Eranga Abeyratne, Joseph R. Freitas, Ali Zaid, Suresh Mahalingam, Adam Taylor   +4 more
openaire   +4 more sources

Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling [PDF]

, 2010
Chikungunya virus (CHIKV) is an emerging human pathogen transmitted by mosquitoes. Like that of other alphaviruses, CHIKV replication causes general host shutoff, leading to severe cytopathicity in mammalian cells, and inhibits the ability of infected ...
Ligtenberg, M., Suhrbier, A., Corinne Geertsema, Esther Schnettler, Fros, J., Just M. Vlak, Maarten Ligtenberg, Geertsema, C., Suhrbier, Andreas, Wen Jun Liu, Natalie A. Prow, Vlak, J.M., Dana L. Vanlandingham, Ligtenberg, Maarten, Khromykh, Alexander A., Jelke J. Fros, Vanlandingham, D.L., Vlak, Just M., Schnettler, E., Fros, J.J., Gorben P. Pijlman, Pijlman, G.P., Liu, W.J., Khromykh, A.A., Prow, A., Fros, Jelke J., Vanlandingham, Dana L., Liu, Wen Jun, Geertsema, Corinne, Prow, Natalie A., Alexander A. Khromykh, Schnettler, Esther, Pijlman, Gorben P., Andreas Suhrbier, Prow, N.A.   +34 more
core   +1 more source

Recent Progress in Vaccine Development Against Chikungunya Virus

Frontiers in Microbiology, 2019
Chikungunya fever (CHIKF) is an acute infectious disease that is mediated by the mosquito-transmitted chikungunya virus (CHIKV). People infected with CHIKV may experience high fever, severe joint pain, skin rash, and headache.
Shan Gao, Siqi Song, Siqi Song, Leiliang Zhang   +3 more
doaj   +1 more source

Challenges in Surveillance for Chikungunya Virus (CHIKV) Infection

Online Journal of Public Health Informatics, 2015
We describe challenges and lessons learned using biosurveillance methods for identifying Chikungunya (CHIKV) infections. Surveillance was performed using VA ESSENCE, electronic laboratory data and facility reports. As of Aug. 14, 2014, 21 confirmed/probable cases were identified at 10 hospitals.
Lucero-Obusan, Cynthia A., Schirmer, Patricia, Oda, Gina, Holodniy, Mark   +3 more
openaire   +2 more sources